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Previewsmercaptoacetamide moiety of 2 was
hydrolyzed to the active thiol and accumu-
lated in the worms in this form, thus vali-
dating the prodrug approach.
It is clear that with the rapid rise of
multidrug resistant infections, new and
innovative ways to combat bacterial
threats are needed. The manuscript by
Janda and coworkers (Zhu et al., 2015)
not only describes the identification and
characterization of a potent inhibitor of
LasB with in vivo efficacy, but also vali-
dates the relevance of LasB as an antivir-ulence target. Furthermore, the use of
a C. elegans disease model to identify
inhibitors of LasB has the potential to
translate to numerous other bacterial
virulence factors, opening up a new
pathway for the identification of much
needed alternative antibacterial agents.
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In this issue, Young, Moody, and colleagues report the discovery of an isomer of the Mycobacterium
tuberculosis (Mtb) virulence factor 1-tuberculosinyl adenosine,N6-tuberculosinyl adenosine, inmice infected
with tuberculosis. These Mtb-derived terpene compoundsmay serve as sensitive and specific biomarkers of
infection.With the rapid increase in antibiotic drug
resistance (Centers for Disease Control
and Prevention, 2013; World Health
Organization, 2014), there is renewed
interest in the development of new




resistant-bacteria), as well as novel ap-
proaches to chemotherapy (Oldfield and
Feng, 2014). One approach to new
therapeutics is to target virulence factors.
Virulence factors are generally used
by bacterial and fungal pathogens
to circumvent host defenses, such as
those provided by neutrophils and
macrophages. One example is that of
the isoprenoid virulence factor, staphy-
loxanthin, in Staphylococcus aureus.
This polyene acts as a ‘‘shield’’ against
host defenses (reactive oxygen species)
and is a target for chemotherapy (Liu
et al., 2008). Another virulence factor
is the isoprenoid tuberculosinyl adeno-
sine (Layre et al., 2014), found in theorganism Mycobacterium tuberculosis
(Mtb), the causative agent of tuberculosis.
This diterpene virulence factor is synthe-
sized from the basic building blocks
of isoprenoid biosynthesis, isopentenyl
diphosphate (Figure 1, 1) and dimethylallyl
diphosphate (2), which condense to
form geranyl diphosphate (3), then farne-
syl diphosphate and geranylgeranyl
diphosphate (GGPP; 4), in reactions
carried out by a series of head-to-head
trans-prenyl synthases. In Mtb, GGPP
is then cyclized by a class II terpene
cyclase (Rv3377c) to form tuberculosinyl
diphosphate (5) (Nakano and Hoshino,
2009), which then alkylates adenosine
on the purine ring at N-1 to form
1-tuberculosinyl adenosine (1-TbAd; 6) in
a reaction catalyzed by tuberculosinyl
adenosine synthase (Rv3378c) (Layre
et al., 2014).
The story of 1-TbAd is a fairly lengthy
one, but in brief: In early work, it was
found that Mtb formed diterpenes, the
tuberculosinols that were later found to
have the same structure as the nosyber-kols extracted from a marine sponge (or
its inhabitants). Hoshino and coworkers
showed that the Rv3377c and Rv3378c
gene products were involved in the
production of these diterpenes, a particu-
larly interesting observation given that
in previous work, Pethe, Russell et al.
(Pethe et al., 2004) had shown that
these gene products were essential for
survival of Mtb inside macrophages.
These cells serve as Mtb’s normal host,
and the diterpene products most likely
accomplish this by preventing phago-
some acidification. These observations
lead to the idea that it might be possible
to kill Mtb inside macrophages by chemi-
cal inhibition of Rv3377c/Rv3378c (Mann
et al., 2009), an anti-virulence approach
to therapy.
Our group (Chan et al., 2014) as well as
Tom Alber’s group (Layre et al., 2014)
separately determined the structure
of Rv3378c, finding that, consistent
with earlier computational predictions,
it adopted the cis-prenyl transferase fold
found in the proteins decaprenylª2015 Elsevier Ltd All rights reserved 437
Figure 1. Biosynthetic Route to 1-TbAd and N6-TbAd
Rv3377c and Rv3378c are potential anti-virulence drug targets; 1-TbAd (6) and N6-TbAd (7) are produced
in vivo in large amounts inMtb-infectedmice and are new targets for diagnosing tuberculosis that are likely
be more specific than, e.g., tuberculin skin tests or interferon gamma release assays.
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Previewsdiphosphate synthase (DPPS) and unde-
caprenyl diphosphate synthase, involved
in bacterial cell wall biosynthesis. More-
over, in one of these papers (Layre et al.,
2014), it was discovered that the actual
biosynthetic product appeared not to be
tuberculosinol (or an iso-tuberculosinol),
but rather 1-TbAd (6), adenosine alkylated
at N1 (Figure 1). This was a quite unex-
pected discovery and is of considerable
interest in the context of drug discovery
targeting virulence. The tuberculosinyl
diphosphate substrate was located in
one structure, and Alber proposed a sec-
ond binding site, into which adenosine
binds. Inhibitor-bound structures were
also reported, and their future develop-
ment may lead to new therapeutics
targeting virulence factor formation
and cell wall biosynthesis—since the
Rv3378c and Mtb DPPS structures are
quite similar.
In this issue, Young et al. (2015) have
made a series of important discoveries.
First, they show that 1-TbAd is pro-
duced in large quantities in Mtb, about
1%–1.5% of Mtb lipids. Second, they
report the discovery of an isomer of438 Chemistry & Biology 22, April 23, 2015 ª1-TbAd, N6-tuberculosinyl adenosine
(N6-TbAd, 7). The Rv3378c enzyme syn-
thesizes 1-TbAd, withN6-TbAd being pro-
duced in a later isomerization involving,
most likely, the Dimroth rearrangement.
Third, 1-TbAd and N6-TbAd are only de-
tected with Mtb. The authors investigated
Mtb and a range of non-tuberculous
mycobacteria, non-actinomycete bacte-
ria, and fungi and found no evidence
for 1-TbAd formation. This opens up a
route to the rapid diagnosis of an Mtb
infection that is more specific than
standard tuberculosis tests (that are
confounded by BCG vaccination or the
presence of other mycobacteria in the
environment). Fourth, the authors find
evidence for both 1-TbAd and N6-TbAd
in a mouse model of infection, using
mass spectrometry. Fifth, the results are
of interest from the perspective of the po-
tential mechanisms of action of 1-TbAd
and N6-TbAd since the authors point
out that the physical properties (such as
computed logP; chromatographic reten-
tion times) of the two isomeric com-
pounds are quite different and lead to
the idea that they could be involved is2015 Elsevier Ltd All rights reservedaffecting host cell lysosome/phagosome
acidification/maturation, acting perhaps
as uncouplers.
In summary, the most important con-
clusion of the paper by Young, Moody,
et al. is that the two isomeric diterpene
nucleosides, 1-TbAd and N6-tuberculo-
sinyl adenosine, are produced, to date,
exclusively by Mtb (and its infected
host). They are excreted in relatively large
amounts, opening theway to the develop-
ment of rapid and highly specific assays
for diagnosing tuberculosis. While the
actual physiological roles and molecular
mechanisms of action of 1-TbAd (or
perhaps both 1-TbAd and N6-TbAd)
remain to be determined, the current
and recent discoveries of these novel
nucleosides are remarkable in that they
have evaded detection for so long, and
their discovery opens up new routes to
both anti-virulence based therapeutics,
as well as highly specific diagnostics.
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